• High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
  • 6 , 9 The demonstrated efficacy, lack of myelosuppression, and overall tolerability of thalidomide provide a strong rationale for its incorporation in standard induction regimens for patients presenting with NDMM who may be eligible for ASCT. (haematologica.org)
  • Combination vincristine, doxorubicin, and dexamethasone (VAD) is considered a standard infusional induction therapy for younger MM patients prior to HDT and ASCT. (haematologica.org)
  • The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT). (biomedcentral.com)
  • Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
  • We propose that targeting CSF1R on these cells may improve the results of ASCT in MM. (biomedcentral.com)
  • Autologous Stem Cell Transplantation (ASCT) remains the standard of care for newly diagnosed, eligible patients. (themmrf.org)
  • The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). (nature.com)
  • We found that VZV reactivation occurred in 57 (30%) patients, in 8.5% during induction and in 21.5% after ASCT peaking at 8 months after ASCT. (nature.com)
  • By immune fluorescence and Serion Elisa VZV IgG assessment, 90.8% of all patients had specific anti-VZV antibodies at ASCT. (nature.com)
  • Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation ( P =0.009). (nature.com)
  • Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ ( P =0.007). (nature.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
  • Five-year survival has improved dramatically from 36% in 2000 to 53% in 2011, attributed to the advent of novel therapies and greater use of autologous stem cell transplantation (ASCT). (lls.org)
  • Studies showed that Black patients were less likely to initiate timely novel therapy and to be treated with more effective regimens, were half as likely to undergo ASCT, and were referred to ASCT later in the disease course compared to White patients. (lls.org)
  • Patients who undergo outpatient autologous stem cell transplantations (ASCTs) not only report lower costs and higher satisfaction, but they also have lower odds of developing febrile neutropenia and septicemia than patients who undergo inpatient ASCT, according to the results of a new analysis. (ajmc.com)
  • Autologous stem cell transplantation (ASCT) provides a therapeutic option for patients with multiple myeloma and lymphoma who are eligible for transplantation and achieved at least a partial response after combination chemotherapy. (ajmc.com)
  • The first ASCT outpatient program was developed in 1993 in order to reduce costs and improve the quality of life for patients who require the transplantation. (ajmc.com)
  • The meta-analysis included 9 studies, comprising of 1940 patients (740 in the outpatient-ASCT arm and 1200 in the inpatient-ASCT arm). (ajmc.com)
  • This meta-analysis is the first to pool together a multitude of studies and conclude that patients who underwent outpatient ASCT had significantly lower odds at developing febrile neutropenia and septicemia than patients who underwent inpatient ASCT. (ajmc.com)
  • Because of the cost savings and higher patient satisfaction rates, outpatient ASCT should utilized in more patients with multiple myeloma and lymphoma when the resources are available. (ajmc.com)
  • If these MM patients meet the eligibility criteria for HDT and ASCT, then this first-line treatment is the current go-to approach, and undeniably a valuable, life-extending one. (janssen.com)
  • Is HDT-ASCT the only option in the frontline for multiple myeloma treatment? (janssen.com)
  • Within 2 months after ASCT or the last VMP cycle, 878 patients were then randomized to VRD consolidation (451 patients) or no consolidation (427 patients), followed by lenalidomide maintenance. (medpagetoday.com)
  • Would you recommend autologous stem cell transplantation (ASCT) for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM)? (targetedonc.com)
  • After 90 months of follow-up, the study found an advantage in progression-free survival [PFS] at 47 months vs 35 months for patients who did not receive ASCT. (targetedonc.com)
  • 1,2 One of the issues is that three-quarters of the patients who did not receive ASCT initially had a stem cell transplant at first relapse. (targetedonc.com)
  • Although the HCT-CI has been investigated in autologous stem cell transplantation (ASCT), its use is limited. (austral.edu.ar)
  • We retrospectively reviewed a cohort of 1730 records of adult patients who received an ASCT in Argentinean center's between October 2002 and August 2016. (austral.edu.ar)
  • Note: For transplant-eligible patients enrolled to Part 1 or Part 2, induction plus conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen. (who.int)
  • Bone Marrow Transplantation , 36 (9), 793-796. (elsevierpure.com)
  • A bone marrow biopsy will be done in order to rule out multiple myeloma. (wikipedia.org)
  • Patients with multiple myeloma typically have a preceding phase of disease in which there are changes in the bone marrow but no symptoms or organ damage. (themmrf.org)
  • Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. (nature.com)
  • Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. (nature.com)
  • Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
  • Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • Patients with low monthly family income (OR=3.14, p=0.010) and complications of MM bone disease (OR=2.95, p=0.029) were more likely to belong to class 2. (bmj.com)
  • Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
  • Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide which is usually calculated based on the patient's weight. (slideshare.net)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
  • Aplastic anemia (AA), the myelodysplastic syndromes (MDS), and paroxysmal nocturnal hemoglobinuria (PNH) are rare diseases that all result in bone marrow failure-the ineffective formation of circulating blood cells-leading to anemia, bleeding, infection, and death in many cases, even with modern therapies. (bloodline.net)
  • A 78-year-old woman with lung adenocarcinoma and multiple bone metastases received maintenance therapy with pemetrexed + pembrolizumab for a year. (journaltocs.ac.uk)
  • The NCCN recommends that a patient whose bone survey is negative should be assessed for bone disease with whole-body MRI or PET/CT. (medscape.com)
  • Amyloidosis is often secondary to MM, but it may develop without MM. Patients with amyloidosis typically lack sufficient numbers of plasma cells in the bone marrow or sufficiently high levels of M protein to meet the diagnostic criteria for MM. (medscape.com)
  • Multiple myeloma is a blood cancer that starts in the plasma cells in the bone marrow. (medlineplus.gov)
  • The bone marrow makes blood cells. (medlineplus.gov)
  • In people with multiple myeloma, abnormal plasma cells grow out of control in the bone marrow and form tumors in the areas of solid bone. (medlineplus.gov)
  • It also makes it harder for the bone marrow to make healthy blood cells and platelets. (medlineplus.gov)
  • As the cancer cells grow in the bone marrow, you may have bone pain, most often in the ribs or back. (medlineplus.gov)
  • An autologous bone marrow or stem cell transplantation is performed using a person's own stem cells. (medlineplus.gov)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Malignant plasma cells in meningeal MM out of 2000 patients with bone marrow produce an immunoglobulin, MM, was reported was by Schluterman et al. (who.int)
  • The prevalence production, lytic lesions and increased of leptomeningeal infiltration in breast can- plasma cells in the bone marrow [ 1 ]. (who.int)
  • MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (who.int)
  • A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. (cdc.gov)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • This study will examine the role of health insurance and living in states with expanded eligibility for Medicaid on treatment patterns and survival in African Americans compared to White patients with multiple myeloma. (lls.org)
  • However, Black patients may not have enjoyed as much survival gain as White patients, possibly due to inequity in access to healthcare. (lls.org)
  • Considering the observations of similar or better survival in Black patients compared to White patients, both given MM treatment, identifying sources of racial disparities in treatment may help enhance survival in Black patients. (lls.org)
  • Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an incurable disease with a median survival of approximately 30 months. (drugpatentwatch.com)
  • Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San MJ: Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. (karger.com)
  • Adding thalidomide to a standard regimen of high-dose chemotherapy in patients with the cancer multiple myeloma improved complete responses but did not give any advantage in five-year survival, according to a study published in the New England Journal of Medicine (March 9). (pharmatimes.com)
  • Differential MIR-21 expression in plasma from mesenteric versus peripheral veins: an observational study of disease-free survival in surgically resected colon cancer patients. (ub.edu)
  • For many years palliation of symptoms with alkylating agents or hydroxyurea was the only therapy available and this had little or no effect on the survival of patients with MF. (bloodline.net)
  • Researchers reported significant improvements in 5-year relative survival among older patients with multiple myeloma who were diagnosed from 1982 to 2017. (hematologyadvisor.com)
  • Patients with multiple myeloma (MM) had significant improvements in 5-year relative survival across all age groups since 1982, according to study results published in the British Journal of Haematology . (hematologyadvisor.com)
  • To investigate the country's trends in incidence and relative survival in MM, the investigators separated all patients who were diagnosed with MM between 1982 and 2017 (excluding incidental MM diagnosed at death/autopsy or no follow up) into 3 age-based categories: younger than 65 years (transplant eligible), 65 to 79 years (youngest transplant ineligible) and aged 80 years or older (oldest transplant ineligible). (hematologyadvisor.com)
  • For patients younger than 65 years, the 5-year and 10-year relative survival steadily increased over all time periods. (hematologyadvisor.com)
  • For patients aged 65 to 79 years, both 5-year and 10-year relative survival were stable until approximately 1998 to 2002, corresponding to the introduction of thalidomide, after which both increased. (hematologyadvisor.com)
  • For patients aged 80 years or older, the 5-year relative survival increased from the first to last time period from 0.11 to 0.28). (hematologyadvisor.com)
  • Improved [relative survival] in patients aged ≥80 years at the time of diagnosis is only rarely described in other population-based studies," wrote the authors. (hematologyadvisor.com)
  • Langseth ØO, Myklebust TÅ, Johannesen TB, Hjertner Ø, Waage A. Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982-2017 [published online May 5, 2020]. (hematologyadvisor.com)
  • 44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT) içinde (566-567. (medipol.edu.tr)
  • Atkinson K, Meyers J, Storb R, Prentice RL, Thomas ED . Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. (nature.com)
  • Infection with varicella-zoster virus after marrow transplantation. (nature.com)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • Furthermore, the infection itself can pathogenetically contribute to the progression of MM through different mechanisms, such as robust production of promyeloma cytokines (e.g., interleukin-6) and activation of Toll-like receptors on malignant plasma cells [ 6 - 10 ]. (jcancer.org)
  • The five-year study revealed that the complete response rate among the Thalomid group, defined as the disappearance of malignant cells in the blood, was 62%, significantly higher than the 43% seen in the control group. (pharmatimes.com)
  • All patients with malignant lung diseases will be supported inderdisciplinarily by the collegues of the University CancerCenter to safeguard the post possible way of treatment. (uniklinikum-dresden.de)
  • Leukemia is a malignant condition involving the excess production of immature or abnormal leukocytes, which eventually suppresses the production of normal blood cells and results in symptoms related to cytopenias. (msdmanuals.com)
  • Malignant transformation usually occurs at the pluripotent stem cell level, although it sometimes involves a committed stem cell with more limited capacity for self-renewal. (msdmanuals.com)
  • Abnormal proliferation, clonal expansion, aberrant differentiation, and diminished apoptosis (programmed cell death) lead to replacement of normal blood elements with malignant cells. (msdmanuals.com)
  • 50 × 10 9 /L) not caused by malignant transformation of a hematopoietic stem cell. (msdmanuals.com)
  • Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. (nature.com)
  • Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation. (austral.edu.ar)
  • The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) score is a useful tool to assess the risk for nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation. (austral.edu.ar)
  • High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies. (elsevierpure.com)
  • This booklet describes current therapies for myeloma as well as emerging treatment options that are being tested in clinical trials. (themmrf.org)
  • This activity has been developed to present and discuss current recommended strategies for individualizing treatment plans for patients with RRMM by incorporating the most up-to-date clinical evidence on sequencing small molecule-based therapies and BCMA-targeted therapies that achieve durable remission while minimizing toxicity. (themmrf.org)
  • Innovation in this area of medicine has been needed, and today's approval of [motixafortide] addresses the demand for new therapies that can meet today's challenges by delivering more reliability in stem cell mobilization, [vs] filgrastim alone, with fewer days of apheresis sessions and fewer doses of filgrastim for people living with this cancer. (cancernetwork.com)
  • Various changes in the field over the past decade, including the frequent use of tandem aHSCT in MM, the advent of novel therapies for the treatment of MM and NHL, plus the addition of new stem cell mobilization techniques, have led to the need to reassess current stem cell mobilization strategies. (bloodline.net)
  • Much of the current confusion and controversy in MDS treatment stems from the lack of consensus on which therapies to use in which patients, and what realistic outcomes might be. (bloodline.net)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitory cell transplantation. (nature.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • However soon after the drug's release in Europe reports linked thalidomide to causing peripheral neuropathy in adult patients (which prevented its licensing and general release in the USA) as well as being behind the occurrence of a high and sudden increase of rare birth defects [ 3 , 5 - 8 ]. (hindawi.com)
  • Dr. Kelsey was concerned about the peripheral neuropathy side effect that had been experienced and reported in some patients in Europe following thalidomide exposure [ 3 , 5 , 25 , 26 ]. (hindawi.com)
  • The FDA has approved motixafortide (Aphexda) combined with filgrastim (G-CSF) to aid in mobilizing hematopoietic stem cells in the peripheral blood for collection, as well as succeeding autologous stem cell transplantation in a population with multiple myeloma, according to a press release from BioLineRx. (cancernetwork.com)
  • Patients who present with active (symptomatic) multiple myeloma are treated with induction therapy. (medscape.com)
  • Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. (cdc.gov)
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
  • Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
  • Based on its oral administration and the reduced incidence of infection and cytopenia, cyclophosphamide-thalidomide-dexa-methasone may be considered an effective induction therapy option for patients with newly diagnosed multiple myeloma. (haematologica.org)
  • The damage caused by thalidomide was not mutually exclusive, with the majority of children exhibiting damage to multiple organs and tissues [ 3 , 7 ]. (hindawi.com)
  • Last year, Celgene was forced to discontinue a trial of a thalidomide derivative - Revlimid (lenalidomide) - in multiple myeloma patients after patients developed blood clots. (pharmatimes.com)
  • The first six patients in each group will receive PS-341 alone for the first cycle, and thalidomide will be added on day 22. (knowcancer.com)
  • Initially, these patients will receive PS-341 alone and thalidomide will be added subsequently, if deemed safe based on the first 6 patients in each thalidomide dose cohort. (knowcancer.com)
  • Only patients who were not treated with autologous or allogeneic hematopoietic stem cell transplant were included. (jcancer.org)
  • This study was supported by the Dutch Cancer Society, the European Myeloma Network, and by unrestricted grants from Celgene and Janssen. (medpagetoday.com)
  • Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). (cdc.gov)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • He has built a prototype of AI with neural network analysis for patients with chronic myeloid leukemia in chronic phase (CML-CP) for the best treatment decision. (mdanderson.org)
  • A female patient, years of age 56, having no distinct inducement before 5 d but developed fever, coughing, and shortness of breath, presented in People′s Hospital of Zhongshan with community-acquired pneumonia on March 3rd, 2023. (flu.org.cn)
  • Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice. (cancernetwork.com)
  • However, due to complex and varied systemic symptoms, including inflammatory storm, sepsis, acute respiratory failure, tachycardia, coagulopathy, and other extrapulmonary organ injuries, she died 19 days after signs due to severe respiratory failure and multiple organ failure. (flu.org.cn)
  • Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. (drugpatentwatch.com)
  • In general, the first decision made in the management of patients with myeloma who require systemic therapy is whether stem cell transplantation is part of the strategy. (medscape.com)
  • ABSTRACT Multiple myeloma (MM) is a systemic malignancy of pathologic plasma cells that is treat able with chemotherapeutic agents and irradiation, but rarely curable. (who.int)
  • In newly diagnosed MM patients, we propose to examine racial (Black/White) differences in the effects of health insurance and Medicaid expansion on MM treatment patterns and their impact on OS. (lls.org)
  • The 'gold standard": What is the current recommended treatment for newly diasnosed multiple myeloma? (janssen.com)
  • Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm. (cancernetwork.com)
  • Treatment of newly diagnosed myeloma. (medscape.com)
  • This webcast features evidence-based presentations along with patient cases designed to address the nuances of T cell-activating therapy use, identification of patients that are the best candidates for these approaches, and options for patients who may not be candidates for this therapy. (themmrf.org)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • An outstanding faculty of distinguished global experts will present the most recent advances and new perspectives in the field of Multiple Myeloma and plasma disorders, from pathophysiology to diagnosis and therapy, including current challenges and new perspectives. (esh.org)
  • The intrinsic immune dysfunction in combination with therapy-related immunosuppression leads to an increased risk for infections, which is a hallmark of multiple myeloma (MM) and major cause of mortality [ 1 - 5 ]. (jcancer.org)
  • [5] , [6] For me, this raises questions around whether it is the only 'gold standard' front-line therapy, particularly as some patients are ineligible, or whether we should look to other options too. (janssen.com)
  • Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received. (cancernetwork.com)
  • Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments. (cancernetwork.com)
  • We also provide cancer pain therapy and psychooncological support for our patients and their relatives, as well as an explicit internal check-up. (uniklinikum-dresden.de)
  • Adult patients with mucoviscidosis receive comprehensive Treatment including the departments of Endocrinology, physical Therapy, gastroenterology, medical psychology, microbiology etc. (uniklinikum-dresden.de)
  • The patient received liver support therapy, and the serum hepatic enzymes recovered to normal levels. (journaltocs.ac.uk)
  • Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against Alpha and Delta variants in Multiple Myeloma patients. (cdc.gov)
  • Cell Replacement Therapy for Parkinson's Disease - Evaluating the potential of autologous grafting. (lu.se)
  • This booklet describes some of the first steps you will want to take after receiving a myeloma diagnosis, as well as what you can expect from your treatment team. (themmrf.org)
  • The diagnosis was established according to International Myeloma Working Group criteria [ 12 ]. (jcancer.org)
  • The diagnosis and treatment facilities we offer our patients are of the highest standard. (uniklinikum-dresden.de)
  • The most widely accepted schema for the diagnosis of multiple myeloma (MM) uses particular combinations of laboratory, imaging, and procedure findings as diagnostic criteria. (medscape.com)
  • Of these, 27.91% had a main diagnosis indicating the transplantation of Multiple Myeloma (MM), and 58.14 received autologous transplantation. (bvsalud.org)
  • It was observed that the patient had psychological suffering from the diagnosis until the end. (bvsalud.org)
  • The Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and the PROMIS Cognitive Function Short Form were used as research tools. (bmj.com)
  • Despite these clinical improvements, the vast majority of patients eventually experience disease relapse and progression. (biomedcentral.com)
  • however, some patients will eventually relapse. (bloodline.net)
  • 0.05) while GIT toxicity was the most common reason for discharge delays in patients conditioned with melfalan 200 mg/m 2 (8.2% vs 14.7%, NS). (nature.com)
  • 05). Life-threatening cardiac toxicity was not significantly increased in patients with pathologic results before transplant. (slideshare.net)
  • Moreover, none of the patients with an EF less than 50% developed cardiac toxicity. (slideshare.net)
  • Although the occurrence of cardiac toxicity is correlated with a reduction of EF before BMT, life-threatening cardiac toxicity cannot be predicted in individual patients [33]. (slideshare.net)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response. (cdc.gov)
  • Thanks to advances in treatment, over 50% of patients now survive 5 years compared to 35% in 2000. (lls.org)
  • Bong I, Ng CC, Baharuddin P, Zakaria Z: MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy. (karger.com)
  • No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease free for at least three years. (knowcancer.com)
  • Explore our multimedia assets, recordings, publications, and much more to add to your knowledge of multiple myeloma treatment options and related topics. (themmrf.org)
  • Central to MMRF's mission is providing educational content no matter where patients and caregivers may be in the multiple myeloma diagnostic and treatment journey. (themmrf.org)
  • It is indicated for the palliative treatment of multiple myeloma. (medscape.com)
  • Objectives To classify subgroups of cancer-related symptoms in patients with multiple myeloma (MM) during treatment and examine between-group differences in demographic and clinical characteristics in addition to functional status. (bmj.com)
  • Conclusions Patients with MM experienced varying degrees of symptoms during treatment. (bmj.com)
  • A latent class analysis was used to categorise cancer-related symptoms in Chinese patients undergoing treatment for multiple myeloma (MM). (bmj.com)
  • Patient clinical characteristics did not include the evaluation of treatment response. (bmj.com)
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. (smw.ch)
  • Yet, to some this drug is a lifesaver, as it now enjoys renaissance in the treatment for a wide range of conditions including leprosy, multiple myeloma, Behcet's disease, and some cancers. (hindawi.com)
  • Patients with uveitis who are not responding well to steroid treatment and patients who have side effects from other medicines used to treat uveitis (such as cyclosporine, cyclophosphamide, methotrexate or azathioprine) or have refused treatment because of possible side effects of these medicines may be eligible for this study. (drugpatentwatch.com)
  • Allogeneic stem cell transplantation (SCT) results in a high percentage of complete remissions, but it can be associated with significant treatment-related mortality, which has been primarily attributed to conventional myeloablative transplant regimens. (drugpatentwatch.com)
  • Donor immunization with myeloma Id in the setting of a non-myeloablative allogeneic SCT may represent a novel strategy for the treatment of multiple myeloma. (drugpatentwatch.com)
  • The latter drug was approved for another haematological disease, myelodysplastic syndromes - in December 2005, and has been fast-tracked as a multiple myeloma treatment by the US Food and Drug Administration (FDA). (pharmatimes.com)
  • In 2005, the FDA issued an approvable letter for Thalomid in the treatment of multiple myeloma, asking for additional information on the drug. (pharmatimes.com)
  • Janssen EMEA › The 'gold standard' of first-line treatment in multiple myeloma - is it time for a rethink? (janssen.com)
  • For the multiple myeloma (MM) community , these words ring true with every treatment breakthrough that is made: they are actions that bring new hope as we work towards a cure. (janssen.com)
  • however, achieving target collection goals can be difficult in some patients given modern barriers, including the treatment of older patients and use of contemporary induction regimens," primary investigator John DiPersio, MD, PhD, a professor of Medicine, Pathology, and Immunology and director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis, said in the press release. (cancernetwork.com)
  • Given the strong efficacy data shown in the GENESIS trial, which included patients who are representative of the current multiple myeloma patient population, we believe [motixafortide] will play a critical role in addressing unmet needs and introduce a new treatment paradigm for this challenging cancer," Serlin stated. (cancernetwork.com)
  • Our surgeons continually integrate the latest research and techniques into their practice so that patients benefit from the most innovative treatment available, even in cases where the patient's condition has not responded to traditional methods. (uniklinikum-dresden.de)
  • Median duration of maintenance was 35.7 months (IQR 13-78 months) and 31.8 months (IQR 14-88 months), respectively, and at 5 years 35% of patients with consolidation and 30% of those without were still receiving maintenance treatment. (medpagetoday.com)
  • Myeloma today: Disease definitions and treatment advances. (medscape.com)
  • Treatment protocols for multiple myeloma are provided below. (medscape.com)
  • Plasma cell neoplasms (including multiple myeloma) treatment (PDQ) - health professional version. (medlineplus.gov)
  • Also, drastic changes in daily living habits, qualified and responsible for the implementation of changes in body image, long duration of treatment, HSCT since 2004, agreed to the Brazilian Unified periods of hospitalization and protective isolation, Health System, which meets the needs of the feeling of loss of control, fear of death and lack of patients with an indication for transplantation. (bvsalud.org)
  • Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. (snmjournals.org)
  • and umbilical cord blood (PUCB), capable of 2017), associated with the results of the procedure restoring spinal cord function and immunology of and require a process of hospitalization and patients with indication for transplantation, with the prolonged hospital recovery. (bvsalud.org)
  • During a Targeted Oncology case-based roundtable event, Robert A. Vescio, MD, discussed the results of several key trials related to new treatments for patients with transplant-eligible multiple myeloma. (targetedonc.com)
  • Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. (medscape.com)
  • Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19. (cdc.gov)
  • One hundred patients (receiving 123 conditioning regimens) were included in the analysis. (nature.com)
  • Large numbers of myeloid-derived suppressor cells (MDSCs), a mixture of monocytic and granulocytic cells, accumulate during many pathologic conditions, including cancer, infectious diseases, trauma, and sepsis. (biomedcentral.com)
  • The use of a patient's immune system to fight cancer-cancer immunotherapy-is an exciting area of multiple myeloma research. (themmrf.org)
  • Interventions The patients were categorised into subgroups based on cancer-related symptoms using a latent class analysis. (bmj.com)
  • Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
  • Multiple myeloma is the most common blood cancer in African Americans. (lls.org)
  • Multiple myeloma (MM) is the most common blood cancer in Black individuals, who account for 20% of MM cases. (lls.org)
  • LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. (lls.org)
  • Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
  • By blocking the CXCR4 receptor, motixafortide was shown in a Phase 2 study in pancreatic cancer patients to enhance anti-tumoral activity and to ameliorate the pro-tumoral activities by modulating the effector/suppressor cell ratio towards a proinflammatory profile. (fox5sandiego.com)
  • At a median follow-up of 74.8 months, median PFS (adjusted for pretreatment) was 59.3 months for patients assigned to VRD consolidation versus 42.9 months for patients assigned to no consolidation (HR 0.81, 95% CI 0.68-0.96, P =0.016), reported Pieter Sonneveld, MD, of Erasmus MC Cancer Institute in Rotterdam, The Netherlands, and colleagues. (medpagetoday.com)
  • The cancer cells can weaken bones. (medlineplus.gov)
  • Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study. (cdc.gov)
  • New insights into genetic characteristics between multiple myeloma and COVID-19: An integrative bioinformatics analysis of gene expression omnibus microarray and the cancer genome atlas data. (cdc.gov)
  • RÉSUMÉ Le myélome multiple est un cancer systémique caractérisé par des cellules plasmatiques anormales, qui peut être traité par des agents chimiothérapeutiques et par irradiation, mais qui est rarement curable. (who.int)
  • Multiple myeloma (MM) is a cancer of the The largest series, 23 patients with lepto- plasma cells. (who.int)
  • Patients that are treated in outpatient or hospital environments may receive different surveys. (pennmedicine.org)
  • A 59-year-old man with a history of IgG kappa multiple myeloma presented to an outpatient facility for evaluation of left hip pain, which was found to be a pathologic fracture. (medscape.com)
  • Despite further resuscitative efforts, the patient died 13 hours after his initial presentation at the outpatient facility. (medscape.com)
  • Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation. (cdc.gov)
  • Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. (elsevierpure.com)
  • Our goal is to share resources and insights on clinical progress and precise treatments for all patients and their caregivers. (themmrf.org)
  • The identification of patients with high symptom burden management should focus on the assessment of demographic and clinical characteristics, in addition to functional status. (bmj.com)
  • This study assessed between-group differences in the demographic and clinical characteristics and functional status of patients with MM. (bmj.com)
  • Over 100 free commonly used clinical formulas and calculator tools to help diagnose, treat, prevent, and determine prognosis of patients at point of care. (guidelinecentral.com)
  • Identify clinical preventive services that are appropriate for your patients. (guidelinecentral.com)
  • NCCN Clinical Practice Guidelines in Oncology, Multiple Myeloma Version 3.2016. (medscape.com)
  • 14: Laurell H, Hansson LE, Gunnarsson U. Impact of clinical experience and diagnostic performance in patients with acute abdominal pain. (cancercentrum.se)
  • Light chain deposition disease (LCDD) is a rare blood cell disease which is characterized by deposition of fragments of infection-fighting immunoglobulins, called light chains (LCs), in the body. (wikipedia.org)
  • Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue. (nature.com)
  • On March 19, 2013, a patient from United Arab Emirates who had severe respiratory infection was transferred to a hospital in Germany, 11 days after symptom onset. (cdc.gov)
  • Based on our earlier research into the main characteristics and risk factors for infections in hospitalized patients with multiple myeloma, we created the numerical Multiple Myeloma Index for Risk of Infection (MMIRI) to predict infection in myeloma patients. (jcancer.org)
  • We tried to create the numerical Multiple Myeloma Index for Risk of Infection (MMIRI) to predict infection in myeloma patients and help identify patients who have a higher risk for developing infections. (jcancer.org)
  • Plasma cells help your body fight infection by producing proteins called antibodies . (medlineplus.gov)
  • Contact your provider if you have multiple myeloma and you develop an infection, or numbness, loss of movement, or loss of sensation. (medlineplus.gov)
  • After 5 years, about 37% of patients with LCDD are alive and do not have end stage renal disease. (wikipedia.org)
  • This booklet is designed to help patients with multiple myeloma - and their friends, families, and caregivers - better understand this disease: what myeloma is and how it develops within the body. (themmrf.org)
  • Disease burden due to HZ was assessed as high or rather high in 70% of the patients. (nature.com)
  • It has also improved symptoms in patients with rheumatoid arthritis, and the Food and Drug Administration has approved it for treating patients with this disease. (drugpatentwatch.com)
  • In a subgroup of 226 patients with stringent complete response, complete response, or very good partial response before start of maintenance, minimal residual disease (MRD) analysis by flow cytometry demonstrated a 74% MRD-negativity rate in VRD-treated patients. (medpagetoday.com)
  • The subgroup analysis by minimal residual disease [MRD] status, or by risk status, showed that the patients with high-risk cytogenetics seemed to derive less benefit from high-dose chemotherapy and a stem cell transplant, 2 which is the opposite of what you would expect. (targetedonc.com)
  • So I think it's clear that lenalidomide alone isn't adequate if patients have high-risk disease. (targetedonc.com)
  • The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
  • A single dose of motixafortide results in achievement of stem cell collection goal in patients with multiple myeloma. (cancernetwork.com)
  • Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma. (cdc.gov)
  • Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination. (cdc.gov)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • Data were collected between March and September of 2016, through the evaluation of the medical records of 43 patients who underwent HSCT and developed some type of psychological distress. (bvsalud.org)
  • A type and antibody screen specimen obtained before the transfusions revealed that his red cells were type B positive, a screen for unexpected antibodies was negative, and direct antibody tests (DAT) for both anti-IgG and anti-C3b were also negative. (medscape.com)
  • Additionally, based on the original protocol, if ≥3 of the planned 10 patients within the pilot phase experienced a partial response (PR) by RECIST criteria within 16 weeks, the combination would be considered promising and an expansion cohort of an additional 30 patients would be initiated for enrollment. (kron4.com)
  • Earlier this year, following a review of the pilot phase data, the trial was amended to become a randomized study, with planned enrollment increasing from 30 to 102 patients. (kron4.com)
  • The injectable agent's approval was supported by data from part 2 of the double-blind, placebo-controlled phase 3 GENESIS study (NCT03246529) in which the potential of motixafortide and filgrastim in mobilizing stem cells for transplantation was assessed vs placebo. (cancernetwork.com)
  • MDSCs are characterized by myeloid origin, immature state, and most importantly by their potent ability to suppress different aspects of immune responses, especially T cell proliferation and cytokine production [ 7 ]. (biomedcentral.com)
  • Motixafortide leverages the expression of the CXCR4 receptor on different immune cells and potentiates the immune system against the tumor. (kron4.com)
  • Among CXCR4-expressing immune cells, some exhibit anti-tumoral activity, such as effector T cells and some exhibit pro-tumoral activity and support tumor growth. (fox5sandiego.com)
  • Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. (cdc.gov)